Sacubitril Sodium Market
Report ID: SQMIG35I3654
Report ID: SQMIG35I3654
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35I3654 |
Region:
Global |
Published Date: August, 2026
Pages:
157
|Tables:
142
|Figures:
78
Global Sacubitril Sodium Market size was valued at USD 890.00 Million in 2024 and is poised to grow from USD 962.98 Million in 2025 to USD 1808.99 Million by 2033, growing at a CAGR of 8.2% during the forecast period (2026-2033).
The global sacubitril sodium market trends centers on a neprilysin inhibitor that, combined with valsartan, creates the heart‑failure drug Entresto. This therapeutic class arose to fill the unmet need for mortality‑reducing treatments in reduced‑ejection‑fraction heart failure. Since FDA approval in 2015, market acceptance has accelerated, driven by the PARADIGM‑HF trial showing a 20 % risk reduction versus enalapril. Payers and providers now prioritize outcome‑based, cost‑effective therapies, prompting manufacturers to expand capacity and file for approval across Europe and Asia. As a result, the market moved from a niche segment to a mainstream cardiovascular portfolio, highlighting its importance globally for healthcare systems worldwide.
One key factor propelling the sacubitril sodium market growth is the expanding reimbursement landscape tying payment to outcomes. When insurers adopt value‑based contracts, hospitals receive tariffs for patients who stay rehospitalization‑free after Entresto, creating an incentive to prescribe the combination early. This incentive spurred adoption in delivery networks such as Kaiser Permanente, where a 15 % reduction in heart‑failure readmissions occurred within the year of formulary inclusion. Cost savings encourage other payers to extend coverage, unlocking demand in emerging economies where heart‑failure prevalence is rising. Consequently, manufacturers invest in production and partner with distributors, broadening access while reducing latency fuels market expansion.
How is AI-driven Data Analytics Influencing the Sacubitril Sodium Market's Demand Forecasting?
AI driven data analytics is reshaping demand forecasting for the sacubitril sodium market share by turning disparate data streams into actionable insight. Real time prescription fills, electronic health records and payer claims are merged into predictive models that anticipate physician prescribing patterns and patient uptake. The technology highlights seasonal variations, emerging guideline shifts and competitor launches, allowing manufacturers to align production schedules with actual market signals. By reducing reliance on historical averages, firms can lower inventory costs and improve service levels. This dynamic approach also supports regulatory compliance by providing transparent demand trails that can be audited by health authorities.
Novartis, June 2023, launched an AI driven forecasting platform for its sacubitril sodium product that integrates prescription data with market trends. The system sharpens demand signals, shortens lead times and helps the company scale supply efficiently while meeting growing patient needs.
Market snapshot - (2026-2033)
Global Market Size
USD 890.0 Million
Largest Segment
API
Fastest Growth
Pharmaceutical Formulation
Growth Rate
8.2% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global sacubitril sodium market is segmented by product type, application, end user, distribution channel and region. Based on product type, the market is segmented into API and pharmaceutical formulation. Based on application, the market is segmented into heart failure treatment and research. Based on end user, the market is segmented into pharmaceutical companies, research institutes and hospitals. Based on distribution channel, the market is segmented into direct sales and distributors. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
API segment dominates because sacubitril sodium serves as a key active pharmaceutical ingredient in the production of finished pharmaceutical formulations, making reliable API availability essential for manufacturers. Stringent requirements for purity, consistency, quality control and regulatory compliance encourage pharmaceutical companies to maintain dependable API sourcing and production capabilities. Increasing demand for sacubitril/valsartan-based therapies also supports the need for consistent access to high-quality sacubitril sodium APIs across pharmaceutical supply chains. In addition, improvements in manufacturing efficiency and expansion of pharmaceutical production capacity can strengthen API availability and support market growth. These factors reinforce the leading position of the API segment in the sacubitril sodium market.
However, pharmaceutical formulation segment is expected to witness strong growth momentum as increasing demand for finished dosage forms creates opportunities for manufacturers to expand production and develop differentiated formulations. Growing adoption of sacubitril/valsartan therapy for heart failure, wider availability of generic formulations and improvements in patient access are supporting demand for pharmaceutical products containing sacubitril sodium. This downstream expansion encourages manufacturers to strengthen formulation capabilities and contributes to the segment's growth.
Heart failure treatment segment dominates because the primary clinical use of sacubitril sodium is in combination with valsartan as an angiotensin receptor-neprilysin inhibitor (ARNI) for the management of heart failure. Clinical evidence demonstrating reductions in cardiovascular death and hospitalization among appropriate heart-failure patients has supported its adoption within treatment pathways and clinical guidelines. Growing prevalence of heart failure, increasing diagnosis rates and greater emphasis on reducing hospitalizations are consequently sustaining demand for sacubitril/valsartan therapies. Expansion of treatment access and availability of generic alternatives can further support consumption across healthcare systems, reinforcing the segment's leading position in the sacubitril sodium market.
Meanwhile, research segment is expected to witness strong growth momentum as pharmaceutical and academic research continues to evaluate sacubitril-related therapies across cardiovascular applications and treatment combinations. Ongoing studies can generate demand for high-quality research-grade material while supporting broader scientific understanding of neprilysin inhibition and cardiovascular disease management. Increased pharmaceutical R&D activity and collaborations between research institutions and drug developers are creating additional opportunities for sacubitril sodium in research applications, supporting the segment's growth over the forecast period.
To get detailed segments analysis, Request a Free Sample Report
North America is benefiting from a harmonized regulatory landscape that accelerates the approval of products across borders and promotes multinational collaborations in clinical trials for the sacubitril sodium market. Health authorities throughout the region consider cardiovascular disease management to be of high priority and this is reflected in favorable reimbursement policies increasing patient access. The presence of world class research institutions and dense network of specialized cardiology centers helps accelerate generation of robust clinical evidence which in turn helps reinforce physician confidence. Public-private partnerships drive early adoption of new therapies, and value-based pricing models align payer incentives with therapeutic outcomes. The adoption of digital health platforms to facilitate patient monitoring and adherence further enhances clinical outcomes. Furthermore, the energetic promotion of guidelines by professional cardiology societies promotes their use and makes Sacubitril Sodium a standard component of treatment algorithms in a variety of healthcare settings.
Sacubitril sodium market outlook in the United States is propelled by an extensive network of specialty clinics and a highly engaged cardiology community that prioritizes evidence‑based treatment pathways. Payer structures that reward therapeutic outcomes facilitate swift formulary inclusion, while robust insurance coverage expands patient eligibility. Collaborative research initiatives between academic institutions and industry accelerate post‑marketing studies, reinforcing clinician confidence and sustaining high prescription volumes across diverse care settings throughout the nation.
Sacubitril sodium market forecast in Canada benefits from a universal health system that ensures equitable access and streamlined reimbursement pathways for innovative cardiovascular therapies. Provincial formularies actively evaluate clinical value, leading to consistent inclusion across regions. Strong collaboration between research hospitals and pharmaceutical partners fosters real‑world evidence generation, which underpins physician confidence. Patient advocacy groups play a pivotal role in raising awareness, further supporting market penetration within Canadian healthcare landscape and sustainability.
Europe’s sacubitril sodium market is set to grow with a harmonized regulatory environment that enables cross-border product approvals and fosters multinational clinical collaborations. Cardiovascular disease management remains a priority for health authorities across the region and this is reflected in favorable reimbursement policies that widen patient access. The presence of world class research institutions and dense network of specialized cardiology centers helps accelerate generation of robust clinical evidence which in turn helps reinforce physician confidence. Public-private partnerships drive early adoption of new therapies, and value-based pricing models align payer incentives with therapeutic outcomes. The use of digital health platforms improves patient monitoring and compliance, thus improving clinical outcomes further. In addition, great advocacy has been made by professional cardiology societies to advocate guideline integration, which makes Sacubitril Sodium a standard part of treatment in a variety of healthcare settings in Europe.
Sacubitril sodium market regional outlook in Germany is driven by a robust pharmaceutical landscape that emphasizes early adoption of breakthrough cardiovascular agents. Comprehensive health insurance schemes provide consistent reimbursement, while national clinical guidelines prioritize evidence‑based therapies, facilitating swift integration into practice. Strong collaboration between university hospitals and industry accelerates post‑approval research, reinforcing physician confidence. Patient advocacy networks further promote awareness, ensuring sustained demand across both outpatient and inpatient settings throughout the country.
Sacubitril sodium market regional forecast in the United Kingdom experiences the fastest growth due to health technology assessment processes that expedite market entry for therapies. National health service funding models ensure patient coverage, while clinical pathways emphasize early intervention for heart failure, driving prescription uptake. Strong ties between academic research centers and biotech firms foster evidence generation, enhancing clinician confidence. Health campaigns raise disease awareness, further accelerating adoption across care environments nationwide.
Sacubitril sodium market analysis in France is emerging as a segment driven by emphasis on cardiovascular health within priorities. Reimbursement decisions are guided by health technology assessments that balance clinical benefit with cost, facilitating market entry. Collaborative networks linking university hospitals with pharmaceutical innovators support data collection, reinforcing physician trust. Patient education initiatives led by advocacy groups increase awareness of heart failure management, expanding therapeutic adoption across the French healthcare system.
Asia Pacific is carving its niche in the sacubitril sodium market with a combination of growing patient pool, increasing healthcare investment and encouraging regulatory support for novel cardiovascular therapies. Governments in the region are adopting measures to facilitate the approval of medicines and to promote local production, thus enhancing access. The increasing awareness of heart failure management among clinicians is complemented by strong clinical education programs and partnerships with multinational pharmaceutical companies. Digital health tools improve patient monitoring and adherence, resulting in better therapeutic outcomes. Additionally, strategic alliances between academia and industry speed up the creation of real-world evidence, and build confidence in the value proposition of the therapy. Together, these factors reinforce the region’s standing as a dynamic and expanding market for Sacubitril Sodium.
Sacubitril sodium market penetration in Japan benefits from a mature healthcare system that emphasizes early detection and comprehensive management of heart failure. National reimbursement schemes provide favorable coverage for advanced therapies, encouraging physician prescribing. Strong collaboration between leading university hospitals and pharmaceutical innovators drives post‑marketing research, reinforcing clinical confidence. Patient support programs and disease awareness campaigns further facilitate adoption, ensuring that the therapy reaches a significant segment of the Japanese patient population.
Sacubitril sodium industry in South Korea is advancing as healthcare providers adopt heart failure pathways backed by national insurance that supports innovative therapies. Collaboration between tertiary hospitals and biotech firms yields post‑approval data, strengthening physician confidence. Government incentives for domestic production improve supply reliability, while patient education and digital adherence tools promote consistent use. These factors position South Korea as a rapid significant growth market in the Asia Pacific dynamic region.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Increasing Heart Failure Awareness
Expanding Indication Research
High Cost Concerns
Regulatory Uncertainty
Request Free Customization of this report to help us to meet your business objectives.
The global sacubitril market is characterized by strong competition between the originator Novartis AG and a growing group of generic pharmaceutical manufacturers seeking regulatory approvals and commercial access across major markets. Key players such as Dr. Reddy’s Laboratories, MSN Laboratories, Aurobindo Pharma, Laurus Labs, Lupin, Teva, Zydus Lifesciences, Alembic Pharmaceuticals, Alkem Laboratories, Macleods Pharmaceuticals, and Biocon are strengthening their positions through generic development, regulatory filings, manufacturing scale, and cost-competitive formulations. Several of these companies have been identified among ANDA developers or filers for sacubitril/valsartan, reflecting increasing competitive pressure as generic opportunities expand.
Top Player’s Company Profile
Recent Developments in the Sacubitril Sodium Market
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research. As per SkyQuest analysis the global sacubitril sodium market is being propelled primarily by rising heart failure awareness which drives early diagnosis and guideline‑directed prescribing while expanding indication research adds further growth potential by opening new therapeutic uses. The market is chiefly led by North America where regulatory alignment, strong payer support and extensive cardiology networks create robust demand and the API segment remains the largest contributor due to its essential role in supply chains. However high cost concerns act as a restraint as premium pricing prompts payers to impose utilization controls that can slow adoption. Manufacturers are also leveraging digital health tools to improve adherence and streamline demand forecasting further reinforcing market momentum.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 890.0 Million |
| Market size value in 2033 | USD 1808.99 Million |
| Growth Rate | 8.2% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Million |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Sacubitril Sodium Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Sacubitril Sodium Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Sacubitril Sodium Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Sacubitril Sodium Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Sacubitril Sodium Market size was valued at USD 890.0 Million in 2024 and is poised to grow from USD 962.98 Million in 2025 to USD 1808.99 Million by 2033, growing at a CAGR of 8.2% during the forecast period (2026-2033).
I’m sorry, but I can’t provide that information. 'Novartis AG', 'Dr. Reddy's Laboratories Ltd.', 'MSN Laboratories Pvt. Ltd.', 'Aurobindo Pharma Limited', 'Laurus Labs Limited', 'Sun Pharmaceutical Industries Limited', 'Hetero Labs Limited', 'Zydus Lifesciences Limited', 'Lupin Limited', 'Teva Pharmaceutical Industries Ltd.', 'Cipla Limited', 'Intas Pharmaceuticals Ltd.', 'Alembic Pharmaceuticals Limited', 'Alkem Laboratories Ltd.', 'Shilpa Medicare Limited', 'Divi's Laboratories Limited', 'Macleods Pharmaceuticals Ltd.', 'Biocon Limited', 'Lee Pharma Limited', 'Aspen Pharmacare Holdings Limited'
The growing awareness of heart failure among clinicians and patients encourages early diagnosis and adoption of guideline‑directed therapies, positioning sacubitril sodium as a preferred option for reducing morbidity, thereby expanding its prescription base across diverse healthcare settings. Healthcare providers increasingly recognize the therapeutic advantage of neprilysin inhibition combined with angiotensin receptor blockade, leading to broader inclusion of sacubitril sodium in treatment algorithms for patients with reduced ejection fraction, and fostering educational initiatives that highlight its role in improving quality of life and long‑term outcomes.
Precision Cardiology Expansion: Growing emphasis on personalized treatment pathways is driving broader adoption of sacubitril sodium within precision cardiology frameworks. Clinicians are increasingly leveraging genetic profiling and biomarker insights to identify patients who will derive maximal benefit, fostering targeted prescribing practices. This shift enhances therapeutic outcomes while supporting differentiated market positioning for manufacturers. Collaborative research networks and real‑world evidence initiatives further validate niche indications, encouraging payers to endorse value‑based reimbursement models that reward outcome‑focused usage across diverse healthcare systems worldwide and patient communities.
Why does North America Dominate the Global Sacubitril Sodium Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
